Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Diabetes, Obesity & Metabolism|January 6, 2011
Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trialS Del Prato, A H Barnett, H Huisman, et al.
Diabetes, Obesity & Metabolism|July 18, 2013
Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairmentS Macha, P Rose, M Mattheus, et al.
Diabetes, Obesity & Metabolism|January 30, 2013
Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetesT Heise, E Seewaldt-Becker, S Macha, et al.
Diabetes, Obesity & Metabolism|August 3, 2013
Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemiaJ Rosenstock, L J Seman, A Jelaska, et al.
Diabetes, Obesity & Metabolism|August 3, 2013
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trialC S Kovacs, V Seshiah, R Swallow, et al.
Diabetes, Obesity & Metabolism|May 15, 2015
Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetesS E Inzucchi, M A Nauck, U Hehnke, et al.
Diabetes, Obesity & Metabolism|September 15, 2012
Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extensionA H Barnett, S Patel, R Harper, et al.
International Journal of Clinical Pharmacology and Therapeutics|May 6, 2011
Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteersE U Graefe-Mody, T Brand, A Ring, et al.
Diabetes, Obesity & Metabolism|September 8, 2015
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetesR Chilton, I Tikkanen, C P Cannon, et al.
Diabetes, Obesity & Metabolism|December 1, 2010
Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled studyM-R Taskinen, J Rosenstock, I Tamminen, et al.
Pageof 5